Multitasking Multiplex Assays

The development of multiplex companion diagnostics is driven by the need to understand efficacy and safety at both the molecular and phenotypic levels. In the future, personalized therapeutic regimens will be tailored to each patient’s genomic, transcriptomic, and epigenomic profiles to optimize individual outcomes.

For personalized (or precision) medicine to become a sustaining reality, all stakeholders—patients, healthcare professionals, drug development companies, regulatory agencies and payers—must work together.

Advancing multiplex companion diagnostics technology was among the topics discussed at CHI’s “Next Generation Diagnostics Summit,” an event held recently in Washington, DC.

To read more, visit